Scott Whitcup, MD

Scientific Advisory Board

Scott Whitcup MD Cloudbreak Therapeutics Scientific Advisory Board

Dr. Scott Whitcup is the Founder and CEO of Akrivista and Whitecap Biosciences, two companies focused on developing new therapies in ophthalmology and dermatology.

Previously, Dr. Whitcup was the Executive Vice President, Research and Development and Chief Scientific Officer at Allergan where he lead an organization focused on therapeutic areas including ophthalmology, CNS, urology, dermatology, medical aesthetics, anti-infectives, and surgical obesity.

Before Allergan, Dr. Whitcup was the Clinical Director at The National Eye Institute at the National Institutes of Health (NIH), where he led the intramural clinical research program.

Dr. Whitcup has 17 issued and 20 pending US patents. He is a Diplomate of both the American Board of Internal Medicine and the American Board of Ophthalmology, a licensed M.D. in CA, and is on the Clinical Faculty of the Department of Ophthalmology at the Jules Stein Eye Institute, David Geffen School of Medicine. Dr. Whitcup serves on the Board of Adverum Biotechnologies and Anivive Lifesciences. He previously served on the Board of Avanir Pharmaceuticals, Questcor Pharmaceuticals, Menlo Therapeutics, and NightstaRx. He is also a senior advisor to Vivo Capital.

Dr. Whitcup has a B.A. in Neurobiology and Behavior from Cornell University and an M.D. from Cornell University Medical College. He completed his residency in Internal Medicine at the UCLA Medical Center, his residency in Ophthalmology at Harvard Medical School-Massachusetts Eye & Ear Infirmary, and a fellowship in Uveitis and Ocular Immunology at the National Eye Institute at the National Institutes of Health (NIH).